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Pearl nacre, a biomineralisation product of molluscs, has growing
applications in cosmetics, as well as dental and bone restoration,
yet a systematic evaluation of its biosafety is lacking. Here, we
assessed the biocompatibility of nacre with two human primary
dermal ﬁbroblast cell cultures and an immortalised epidermal cell
line and found no adverse eﬀects.
There are three main types of pearl oysters of the genus
Pinctada: the “Akoya” pearl oyster called Pinctada fucata, the
“Golden lipped” oyster Pinctada maxima and the “Black
lipped” oyster named Pinctada margaritifera. Mollusc shells are
mainly made up of two layers of calcium carbonate, compris-
ing an outer layer of calcite and an inner layer of aragonite.
Nacre (mother of pearl) in all oyster shells is a calcified struc-
ture that forms the lustrous inner layer. It is mainly composed
of aragonite (∼95–97%) tablets oriented in multiple layers,
each surrounded by organic matrix.1,2 This organic matrix
makes up ∼5% of the nacre composition and is mainly com-
prised of polysaccharides and proteins.3 According to a Euro-
pean Commission report published in 2007 the cosmetic and
toiletries industry in the EU, Japan, China and the US had a
total market value of €136.2 billion.4 The cosmetics industry
maintains its edge by constantly developing novel topical skin
treatments. A popular example is the use of all-natural or
organic ingredients, such as fruit and plant extracts to oﬀer
wrinkle relief that mimics the painful and potentially danger-
ous side eﬀects associated with invasive chemical remedies.5
Clinically, topical treatments containing, for example, aloe
vera, vitamin C, corticosteroids and tacrolimus are used with
the aim of minimizing scarring.6 Recently, there has been
interest in the cosmetics industry in the use of nacre as a key
ingredient.7 Most of the formulations are reported to either
use powdered pearl shell or powdered nacreous layer shell.
Powdered shell and powdered nacre comprises of both organic
and inorganic components. It is reported that nacre stores in
its mineral-based organic structure a variety of bioactive mole-
cules. Eﬃcacy of this water soluble matrix (WSM) has been
tested in a porcine burn injury model.8 WSM was obtained by
suspending powdered nacre in ultra-pure water and collecting
the supernatant via precipitation of insoluble components by
centrifugation. It was concluded that the active mineral based
organic component has beneficial eﬀects on the skin with
enhanced wound healing.8,9
Nacre has also attracted attention for its potential in sup-
porting bone grafting and bone regeneration. In culture under
physiological conditions, nacre can transform to hydroxy-
apatite, the phosphorous rich main constituent of the mamma-
lian bone framework.10,11 Nacre and its WSM can also aid in
osteogenic regeneration.9,12–17 High phosphorous rich domains
have been described at the interface between bone and
implants made from Margaritifera shells which are biocompa-
tible, biodegradable and osteoconductive and thus are thought
to promote bone formation.18 Furthermore, nacre powder has
been used as an implantable material for reconstruction and
regeneration of maxillary alveolar ridge bone in humans.19 In
this example, the implanted nacre dissolves gradually and is
eventually replaced by the mature lamellar bone suggesting
that the nacre acts as a biocompatible substrate for bone repla-
cement.19 The water soluble components of the crushed nacre
have also been investigated for their potential in bone regener-
ation in a similar vein.20,21 Lee et al., demonstrated the wound
healing potential of WSM component in a deep burn porcine
skin model and showed enhanced collagen secretion and
deposition at the injury site resulting in enhanced healing.8 In
another in vivo study using a rat skin incisional injury model,
powdered nacre was implanted between the epidermis and
dermis at the incisional site, with an aim of studying the eﬀect
of nacre on the synthesis of certain constituents of the dermal
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extracellular matrix. It was concluded that implanted nacre
increased collagen synthesis by dermal fibroblasts.22 While
extensive investigations have been carried out in bone, the
evaluation of the biocompatibility of nacre with human skin
cells is lacking. Thus the growing number of cosmetic formu-
lations in the market with nacre as a key ingredient7,23,24
clearly warrants a thorough assessment with human skin cells.
Since scars are also common, and contain cells with a pheno-
type distinct from normal skin,25 it is also important to test
potential cosmetic ingredients with both cell types.
In the present study, we use nacre from the inner calcified
layer of the shell of Pinctada margaritifera and report the
in vitro toxicity assessment of the material on three cell types
representing both epidermal and dermal layers of human
skin. These were HaCaT cells, a human derived immortalised
keratinocytes cell line, primary human dermal skin fibroblasts
(HDF) and primary human scar fibroblasts (HSF).
Nacre used in the study was gently scraped26,27 from the
inner layer of the shell to avoid the post processing required in
the case of powdered shell. SEM images (Fig. 1) confirmed
that the nacre was composed of pseudo-hexagonal shaped ara-
gonite tablets which have basal plane dimensions of 2–6 µm,
and a thickness of 300–400 nm.28 This structure is character-
istic of previously reported nacre, which is a composite
material consisting of alternating layers of mineral tablets sepa-
rated by thin layers of biomacromolecular “glue”.29,30
To test the cytotoxicity of nacre, a live/dead assay was
carried out (see ESI S1.4†). Cells were incubated with nacre in
culture media at physiological conditions for 24 h to 72 h and
were then stained for viability using calcein AM/ethidium
bromide I solutions. Viable cells fluoresce green through the
reaction of calcein AM with intracellular esterase, whereas
non-viable cells fluoresce red due to the diﬀusion of ethidium
homodimer across damaged cell membranes and binding with
nucleic acids.
Fig. 2 shows live cells as the percentage of the total cells in
human primary dermal skin fibroblast (HDF), human primary
scar fibroblast (HSF) and human derived immortalised HaCaT
cell cultures when exposed to various concentrations of nacre
for 24 h and 72 h. Cytotoxicity of nacre was not observed for
any of the concentrations examined in HDF cells (Fig. 2a).
However, interestingly at a concentration of 2.5 mg ml−1 of
nacre (highest concentration tested) there was a significant
reduction in viability at both 24 and 72 hours in the HSF cells
(Fig. 2b). This underlines the importance of testing both scar
and normal skin cell types for cosmetic application. Toxicity
was also observed at a concentration of 0.5 mg ml−1 in HaCaT
cells (Fig. 2c), although this was only observed at 24 hours and
Fig. 1 Top view of the scrapped nacre, imaged using scanning electron
microscopy (SEM). Scale bar (a) 1 µM and (b) 2 µM respectively. Sample
was coated with 4 nm platinum prior to imaging.
Fig. 2 Cell viability assays showing percentage of live cells in the
culture post incubation with nacre. (a) Human dermal skin ﬁbroblasts
cells, (b) human scar ﬁbroblasts cells and (c) human derived immorta-
lised HaCaT cells were incubated with various concentrations of
scrapped nacre and treated with calcein AM/ethidium bromide I to stain
for live and dead cells. Both live and dead cells were counted using ﬂuo-
rescence microscopy. ‘None’ is the untreated control. Data presented as
average ± SEM (n = 4). Signiﬁcance was set at *p < 0.05 using bonferroni
test in one way ANNOVA.
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was no longer present at the 72 hour time point. These results
are in line with the results obtained previously where constitu-
ents of nacre were shown to promote wound healing in a rat
model22 and deep burn porcine skin.8 In both these studies,
nacre has been shown to promote the recruitment of fibro-
blasts for restoration and coverage of the injury site while
showing no apparent signs of cytotoxicity. It has also been
shown to promote bone formation when implanted in the
femur of sheep with midshaft hemidiaphysis resection of their
femur in vivo reiterating the non-cytotoxic advantage of
nacre.31
Fibroblasts have been reported to undergo morphological
changes from dendritic to stellate shapes upon exposure to
external cues caused by changes in actin polarisation and
adhesion.32,33 Cell morphology in fibroblasts is known to be
influenced by cytokines such as transforming growth factor β
which can potentially induce polymerisation of globular to
filamentous actin.34 Fibroblast morphology can also be modu-
lated by extracellular matrix architecture during wound
healing via cell–matrix interaction.32 Such morphological
change has been observed in cells undergoing oxidative
stress.35,36 In our study, we found similar changes in fibroblast
morphology for both HDF and HSF cells at the highest concen-
tration of nacre of 2.5 mg mL−1 (Fig. 3). Similar altered mor-
phology was also observed for HaCaT cells (see ESI Fig. S1†). It
could be postulated that the high concentration of nacre
induces cellular stress, resulting in changes in the actin cyto-
skeleton and a more stellate morphology (Fig. 3i, iii, ii and iv).
Cell area was calculated from the fluorescent images shown in
Fig. 3 using Image J software.37 It was found that both HDF
and HSF had significantly larger cell areas (p < 0.05) when
treated with 2.5 mg mL−1 of nacre (HDF: 2.79 ± 0.13 µm and
HSF: 3.0 ± 0.19 µm respectively) as compared to the non-
treated controls (HDF: 1.56 ± 0.08 µm and HSF: 1.54 ± 0.10 µm
respectively) (see ESI Fig. S2†).
Altered fibroblast morphology has been thought to occur in
response to various factors including aging,38 strength of the
extracellular matrix39 or other etiologies that induce mechan-
ical stress on the cell. Changes in morphology also commonly
indicate oxidative as well as mechanical stress.39 Therefore, we
explored whether the morphological changes and increase in
Fig. 3 Cell morphology post calcein AM staining and imaged using
ﬂuorescent microscopy. Cells were treated with various concentrations
of nacre for 24 h, stained and imaged. (i) untreated (control) primary
human dermal skin ﬁbroblasts (HDF), (ii) HDF treated with 0.05 mg mL−1
nacre, (iii) HDF treated with 2.5 mg mL−1 nacre, and (iv), untreated
(control) primary human dermal scar ﬁbroblasts (HSF), (v) HSF treated
with 0.05 mg mL−1 nacre and (vi) HSF treated with 2.5 mg mL−1 nacre.
Scale bar 1 µm.
Fig. 4 Reactive oxygen species (ROS) assay showing ROS levels in cells
stressed with various concentrations of nacre for 24 h. No signiﬁcant
stress was observed as a result of calcium (from nacre) induced oxidative
stress at the concentrations studied. (a) Human dermal skin ﬁbroblasts
cells, (b) human scar ﬁbroblasts cells and (c) human derived immorta-
lised HaCaT cells were incubated with various concentrations of
scrapped nacre for the speciﬁed period of time. Cells were then incu-
bated with 2’,7’-dichlorodihydroﬂuorescein diacetate (DCFH-DA) solu-
tion which ﬂuoresce in the presence of reactive oxygen species. ‘None’
is the untreated control. Data presented as average ± SEM (n = 3). Sig-
niﬁcance was set at *p < 0.05 using bonferroni test in one way ANNOVA.
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cell area at the highest concentration of nacre in culture was a
result of, or induced oxidative stress in, the cells. Oxidative
stress was tested using the cell permeable fluorogenic probe
2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA).
DCFH-DA is taken up by cells and is deacetylated by cellular
esterases to non-fluorescent 2′,7′-dichlorodihydrofluorescein
(DCFH) which is rapidly oxidised by reactive oxygen species
(ROS) to highly fluorescent 2′,7′-dichlorodihydrofluorescein
(DCF). The fluorescent intensity is proportional to the ROS
levels within the cytosol (see ESI S1.5†). Cell responsiveness to
the assay was carried out by stressing the cells with the H2O2
solution provided in the kit which was also used to generate
the calibration curve (see ESI Fig. S3†). No changes in levels of
reactive oxygen species were observed in any cell type at any
concentration of nacre (Fig. 4). This is important as oxidative
stress is known to be a significant contributor to skin damage
and excessive scarring in previous studies.40 It has been
known that cells alter their morphology depending on their
environment.41,42 It is therefore hypothesized that the altered
fibroblast morphology in the present case is mainly due to the
regulation of cell motility through geometrical constraint in
the presence of nacre. Indeed, it has been previously reported
that when cells probe their physical surroundings, they acquire
mechanical information or signals that help to determine the
direction of migration, with a consequential change in cell
morphology.43
Conclusions
We have established the biocompatibility of nacre using three
human cell types representing the two primary layers of
human skin, using immortalised keratinocytes from the epi-
dermal layer and two primary human dermal cell cultures. The
nacre used in the present study showed limited cytotoxicity at
high concentrations in scar derived cells, with the morphology
of the cells significantly changed by exposure at such concen-
trations of nacre. No apparent oxidative stress was evident in
any of the cell types. Overall, the data support the use of low
concentrations of nacre in aesthetic formulations, with the
potential for high concentrations to cause changes in skin
and/or scar cells which may have impact on eﬃcacy.
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